24.13
+1.79(+8.01%)
Currency In USD
| Previous Close | 22.34 |
| Open | 22.65 |
| Day High | 25.12 |
| Day Low | 21.9 |
| 52-Week High | 40.47 |
| 52-Week Low | 14.8 |
| Volume | 2.72M |
| Average Volume | 1.22M |
| Market Cap | 1.84B |
| PE | -17.11 |
| EPS | -1.41 |
| Moving Average 50 Days | 24.04 |
| Moving Average 200 Days | 31.04 |
| Change | 1.79 |
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
GlobeNewswire Inc.
May 01, 2025 12:00 PM GMT
- Award recipients Honored at the American Urological Association's 2025 Annual Meeting - - Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC - SCH
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
GlobeNewswire Inc.
Apr 26, 2025 8:10 PM GMT
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
GlobeNewswire Inc.
Apr 24, 2025 12:00 PM GMT
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladde
